GlassScriptPhysician profile
James A Gaume
NPI 1609970797
$7,791.02
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $278 · 2021: $1,846 · 2022: $2,155 · 2023: $3,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $964.69 | 2019-2023 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $908.73 | 2019-2023 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $663.24 | 2019-2023 | Farxiga |
| Dexcom, INC. | $532.17 | 2020-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $493.53 | 2021-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $466.96 | 2021-2023 | Gvoke Hypopen |
| Amgen INC. | $417.19 | 2020-2023 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $311.59 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $299.23 | 2021-2023 | |
| Medtronic, INC. | $292.69 | 2021-2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.80 | 2021-2023 | Jardiance |
| Mannkind Corporation | $160.97 | 2021 | |
| Amryt Pharma Holdings LTD | $158.91 | 2022-2023 | Mycapssa |
| Abbvie INC. | $157.15 | 2022-2023 | |
| Ascensia Diabetes Care US INC. | $139.48 | 2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $137.87 | 2023 | Cequr Simplicity |
| Abbott Laboratories | $128.87 | 2019-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $112.38 | 2022-2023 | Korlym |
| Antares Pharma, INC. | $99.61 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $93.57 | 2021-2023 | Unithroid |
| Lifescan, INC. | $86.42 | 2020-2022 | |
| Recordati_rare_diseases_inc. | $79.30 | 2021-2023 | Isturisa, Signifor Lar |
| Radius Health, INC. | $78.53 | 2021-2023 | Tymlos |
| Pfizer INC. | $72.25 | 2023 | |
| Esperion Therapeutics, INC. | $66.89 | 2021 | |
| Grt US Holding, INC. | $65.99 | 2022 | |
| Zealand Pharma US, INC. | $64.47 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $62.20 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $61.55 | 2022-2023 | Strensiq |
| Merck Sharp & Dohme LLC | $60.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.48 | 2022-2023 | |
| Amarin Pharma, INC. | $41.89 | 2020-2021 | |
| Clarus Therapeutics INC. | $41.74 | 2021 | |
| Ascendis Pharma Endocrinology INC | $41.19 | 2023 | |
| Companion Medical, INC. | $26.73 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.94 | 2022 | |
| Beta Bionics, INC. | $22.87 | 2023 | Ilet Bionic Pancreas |
| Janssen Pharmaceuticals, INC | $19.88 | 2019 | |
| Halozyme INC | $18.67 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gaume listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.